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Abstract
Background: The management of patients with glioblastoma multiforme is difficult. Poor results have led to a
search for novel therapeutic approaches. Gene therapy that could be both anti-invasive and antiangiogenic would
be ideal. In this study, we constructed the recombinant adenoviral vector Ad-CALR/MAGE-A3 and evaluated its
antitumor effects on glioblastoma in vitro and in vivo.
Methods: In this study, CALR and MAGE-A3 genes were delivered to the glioblastoma cell line U87, using
adenovirus (Ad-CALR/MAGE-A3). U87 glioblastoma cells were transfected with Ad-green fluorescent protein to
identify the multiplicity of infection. The expressions of CALR and MAGE-A3 were detected by PCR and Western
blot. Cell proliferation was measured by MTT assay. Cell apoptosis was assessed by Annexin-V FITC/PI double
staining flow cytometry. The invasive potential of U87 cells was determined by Matrigel invasion assay. Tube
formation assay was used to detect the effects on angiogenesis of human umbilical vein endothelial cells. Protein
expressions of PI3K/AKT, Erk1/2 and MMP-2/-9 in transfected cells were detected by Western blot. In vivo, the
effects of Ad-CALR/MAGE-A3 on tumor growth and angiogenesis of U87 glioblastoma xenografts in nude mice
were investigated.
Results: The expressions of CALR and MAGE-A3 in U87 cells resulted in the suppression of cell proliferation and
invasion properties, and induced cell apoptosis. The Erk MAPK, PI3K/AKT pathways and expressions of MMP-2/-9
were inhibited in Ad-CALR/MAGE-A3-transfected cells. Outcomes of the tube formation assay confirmed the
antiangiogenic effect of CALR. Moreover, in the in vivo model of glioblastoma, intratumoral injection of Ad-CALR/
MAGE-A3 suppressed tumor growth and angiogenesis.
Conclusion: Although Ad-CALR/MAGE-A3 and Ad-CALR demonstrated antiangiogenic effects on U87 cells, the
repression of invasion was significant only in Ad-CALR/MAGE-A3-treated cells. To our knowledge, this is the first
description of a role for combined CALR and MAGE-A3 in the anti-invasion and antiangiogenesis of U87.
Background
T h em o s tf r e q u e n tf o r mo fb r a i nt u m o ri na d u l t si s
glioma [1]. Types of gliomas include astrocytomas, oligo-
dendrogliomas, oligoastrocytomas, and ependymomas
[2]. Astrocytoma is the most common, and on the World
Health Organization’s international classification of
human tumors scale, astrocytomas may carry a histologi-
cal grade anywhere from I (low proliferative potential
and the possibility of cure) to IV (cytologically malignant,
mitotically active, and typically fatal). By contrast, oligo-
dendrogliomas and oligoastrocytomas are usually classi-
fied either grade II or III [3].
The grade IV astrocytic tumor, or glioblastoma, is
highly invasive and clinically challenging. Despite appli-
cation of multimodal therapies, median survival is only
12-15 months [4]. There is a tremendous need to develop
novel approaches to treat glioblastoma, and virus-
mediated gene therapy is a viable possibility. A novel
gene therapy that could achieve an antiangiogenic and
anti-invasive effect would reduce the tumor’sv a s c u l a r
permeability and prolong progression-free survival, and is
therefore critically important.
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testis antigen. Its expression in normal tissues is limited
to the testes but it is found at high levels in various
tumors [5-7]. Indeed, immunotherapeutic trials targeting
MAGE peptides have achieved encouraging results in
patients with metastatic melanoma [8-10]. However,
there is currently limited evidence implicating MAGE-A3
activity in cancer progression. Other MAGE-A gene
members, such as MAGE-A4, have been reported to pro-
mote apoptosis in non-small cell lung cancer [11], and
MAGE-D1 may be a novel endogenous inhibitor of
angiogenesis in vitro and in vivo [12]. The putative func-
tions of MAGE family members highlight the importance
of their detailed characterization with regard to cancer
progression.
Calreticulin (CALR) is an abundant 46-kDa Ca
2+- bind-
ing protein which was first located in the endoplasmic
reticulum [13,14], but is also found at the cell surface
and nucleolus [15,16]; it performs a variety of functions
within the cell [17-19]. Although the role of CALR in
normal cellular functions and embryogenesis is well-
established, the parts it plays in human carcinogenesis
are poorly understood [20]. It has been reported to act as
an endothelial cell inhibitor of tumor growth and its cha-
perone effect in cancer vaccines was also shown [21,22].
Recently, the repressive effect of CALR on tumor inva-
sion, including that of the prostate [23], has become a
popular field of research.
Adenovirus-based transfer of a gene into cells causes a
transient spike in the levels of the protein the gene
encodes. The technique reduces the possibility of experi-
mental error to some extent. To the best of our knowl-
edge, no prior study has attempted the simultaneous
adenovirus-mediated gene transfer of the genes CALR
and MAGE-A3 (Ad-CALR/MAGE-A3) to evaluate their
combined antitumor effect or antitumor mechanism in
glioblastoma. In this study, we successfully used Ad-
CALR/MAGE-A3 to express CALR and MAGE-A3 pro-
teins in the glioblastoma cell line U87. In both in vitro
and in vivo experiments we demonstrate that tumor
growth and invasive abilities are reduced, while apoptosis
is induced, in Ad-CALR/MAGE-A3-transfected U87
cells. In addition, molecular mechanisms underlying the
antitumor effects of Ad-CALR/MAGE-A3 are partially
revealed, which could serve as a rationale for gene ther-
apy in the treatment of glioblastoma.
Methods
Cell lines and cell culture
Cells of the human embryo kidney cell line 293-LP and
human glioblastoma cell line U87 were grown in Dul-
becco’s modified Eagle’s medium (DMEM), supplemen-
ted with 10% fetal bovine serum. Human umbilical vein
endothelial cells (HUVECs) were grown in Kaighn’s
modification of Ham’s F-12 medium (F-12 K), with
0.1 mg/mL heparin, 0.03-0.05 mg/mL endothelial cell
growth supplement, and 10% fetal bovine serum (FBS),
in a humidified atmosphere containing 5% CO2 at 37°C.
All cells were purchased from the Institute of Biochem-
istry and Cell Biology, Shanghai Institute for Biological
Sciences, Chinese Academy of Sciences. All media and
sera were purchased from Gibco.
Adenoviral vector construction and transfection
To create Ad-CALR, a fragment of CALR was excised
using EcoRI/KpnI and cloned into a pShuttle- green
fluorescent protein (GFP)- cytomegalovirus (CMV) plas-
mid to produce the shuttle vector. CALR was subse-
quently excised from the shuttle vector using I-CeuI and
I-SceI and ligated into the pAd vector for the recombi-
nant generation of Ad-CALR. To create Ad-CALR/
MAGE-A3, a fragment of CALR was excised using NheI/
PmeI and cloned into a pShuttle-GFP-CMV plasmid; a
fragment of MAGE-A3 was excised by BglII/XhoI and
cloned into the pShuttle-(ΔGFP)-CALR plasmid. CALR/
MAGE-A3 was subsequently excised from the shuttle
vector using I-CeuI and I-SceI and ligated into the pAd
vector for the recombinant generation of Ad-CALR/
MAGE-A3. Ad-CALR and Ad-CALR/MAGE-A3 were
further amplified in HEK293LP cells. Viral particles were
purified using cesium chloride density gradient centrifu-
gation. 293-LP cells in serum-free DMEM were trans-
fected with Ad-GFP to identify the optimal conditions.
U87 cells (2 × 10
6) were transfected with Ad-vector, Ad-
CALR, and Ad-CALR/MAGE-A3 at 100 multiplicity of
infection (MOI), (calculated as the number of plaque-
forming units [PFU] per cell), in a humidified atmosphere
containing 5% CO2 at 37°C. Transfection with a null plas-
mid served as a control. The cells were harvested 48 h
after transfection for analyses.
Reverse transcription-PCR and real-time quantitative
RT-PCR (qRT-PCR)
All PCR kits were purchased from Takara, Japan. Total
RNA was isolated from cultured cells using an RNAiso
Plus kit (1 mL per 5 × 10
6 cells). The concentration and
purity of RNA were detected by an ultraviolet spectro-
meter. cDNA was generated according to the RNA
reverse transcription (RT) kit instructions. MAGE-A3
fragment was amplified with forward primer 5’-CTGC
TCACCCAACATTTCGT-3’, reverse primer 5’-CACTC
TTCCCCCTCTCTCAA-3’. MAGE-A3/PolyA fragment
was amplified with the forward primer and reverse pri-
mer of PolyA 5’-GTGGTTTGTCCAAACTCATCAA-3’.
PCR conditions were: 95°C for 15 min; 30 cycles of 94°C
for 30 s, 55°C for 30 s, and 72°C for 2 min; and 4°C
hold. Ten microliters of PCR product was analyzed on
2% agarose gels. SYBR
® Premix Ex Taq™ (Perfect Real
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The Light Cycler PCR system (Roche Diagnostics, Man-
nheim, Germany) was used for qPCR amplification and
cycle threshold (Ct) detection. The thermal cycling con-
ditions comprised an initial denaturation step at 95°C
for 30 s, 40 cycles at 95°C for 5 s, and 61°C for 30 s. Pri-
mers were 5’-GCACTTGGATCCACCCAGAA-3’ and
5’-GAAGTTGTCAAAGATGGTGCCAGA-3’. The melt-
ing curves were analyzed after amplification. Each PCR
reaction was done in triplicate.
Relative changes in expression were calculated using the
2
-ΔΔCt method (Reference), where ΔCt is the difference in
threshold cycles for the target gene and reference (ACTB),
and ΔΔCt is the difference between the ΔCts of the treated
sample and control or calibrator. Thus, the expression
levels were reported as fold changes relative to the calibra-
tor. The value was used to plot the expression of apoptotic
genes with the formula 2
-ΔΔCt.
Western blot analysis
Four sub-group U87 cells were lysed in radioimmunopre-
cipitation (RIPA) buffer and total protein concentration
was determined with a bicinchoninic acid (BCA) assay
(Beyotime, China). Twenty micrograms of total protein
were separated by 10% SDS-PAGE and then transferred to
polyvinylidene fluoride membranes. The membranes were
washed, blocked, and incubated sequentially with specific
primary antibodies, namely: rabbit monoclonal anti-CALR
(1:1000), rabbit polyclonal anti-MAGE-A3 (1:100), both
from Abcam (MA, USA); anti-PI3K (1:200), anti-Akt
(1:200)/phosphorylated (p)-Akt (1:200), anti-Erk1/2
(1:200)/p-Erk1/2 (1:200) from Santa Cruz (CA, USA);
mouse monoclonal anti-matrix metalloproteinases (MMP)
2 (1:1000), rabbit monoclonal anti-MMP9 (1:10000) and
rabbit polyclonal anti-b-actin (1:1000) from Abcam. Incu-
bation in primary antibodies was followed by horseradish
peroxidase -conjugated anti-rabbit secondary antibody
(Zhongshan, 1:2000).
The reactions were detected by enhanced chemilumi-
nescence assay. Each experiment was performed in
triplicate.
Cell proliferation assay
Cell proliferation was detected by methyl-thiazolyl-tetrazo-
lium (MTT) assay. U87 cells were seeded in 96-well plates
at a density of 1 × 10
4 cells/well. After 24 h, the cells were
transfected with null, Ad-vector, Ad-CALR or Ad-CALR/
MAGE-A3 and cultured for 1-7 d. Cell proliferation was
determined by adding MTT (5 mg/mL) and incubating
the cells at 37°C for 4 h further. The precipitate was solu-
bilized by the addition of 150 μL/well dimethyl sulfoxide
(Sigma) and shaken for 10 min. Absorbance at a wave-
length of 490 nm was measured in each well with a micro-
plate reader (Bio-Tek ELX800, USA).
In vitro invasion assay
Invasion assays were performed using a 24-well plate inva-
sion chamber (Corning, USA) fitted with cell culture
inserts, and closed with 8 μm pore-size poly(ethylene ter-
ephthalate) (PET) membranes coated with a thin layer of
Matrigel basement membrane matrix (BD Matrigel™).
The lower chamber was filled with 600 μLD M E Ms u p p l e -
mented with 10% FBS added as a chemoattractant. In the
upper chamber, 100 μL of cells previously grown in
DMEM for 12 h were seeded at 2 × 10
5 cells/mL in
serum-free medium. The total number of cells that had
migrated to the underside of the membranes after 48 h
was counted under a light microscope in five predeter-
mined fields (×100) after fixation and staining with crystal
violet. All assays were independently repeated ≥ 3× .
Flow cytometric analysis of apoptosis
Apoptosis was examined by using an fluorescein isothio-
cyanate (FITC) Annexin-V Apoptosis Detection Kit (Bec-
ton Dickinson, San Jose, CA, USA) according to the
manufacturer’s instructions. Briefly, 1 × 10
6 U87 cells were
harvested and washed with cold PBS. The cells were resus-
p e n d e di n1m Lo f1×b i n d i n gb u f f e r .O n eh u n d r e d
microliters were transferred to a 5 mL culture tube, and 5
μL of Annexin V-FITC and 5 μL of propidium iodide (PI)
were added. Cells were vortexed and incubated for 15 min
in the dark. Four hundred microliters of 1 × binding buffer
was added to each tube.
Flow cytometric analysis was performed immediately
after staining. Data acquisition and analysis were per-
formed by a fluorescence-activated cell scanner (FACS)
flow cytometer (Becton Dickinson, San Jose, CA, USA).
Cells in the early stages of apoptosis were Annexin
V-positive and PI-negative, whereas cells in the late
stages of apoptosis were positive for both annexin V
and PI. All assays were independently repeated ≥ 3× .
Tube formation assay
Cells growing in log phase were treated with trypsin and
resuspended as single-cell solutions. A total of 2 × 10
5
HUVEC cells were seeded on Matrigel-coated 96-well
plates. The cells were incubated with U87 supernatant
that had been treated with null, Ad-vectors (MOI = 100),
Ad-CALR vectors (MOI = 100) or Ad-CALR/MAGE-A3
vectors (MOI = 100) at 37°C, 5% CO2 for 48 h. Tube for-
mation was quantified by counting the number of con-
nected cells in randomly selected fields (×100). All assays
were independently repeated ≥ 3× .
Nude mouse xenograft model
Female BALB/c nu/nu mice, 4-5 weeks old, were pur-
chased from Vital River Laboratories (Beijing, China).
Animal treatment and care were in accordance with
institutional guidelines. U87 cells (1 × 10
7)w e r e
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into the right flank of each mouse. After 2 weeks, the
tumor volume had reached 50-100 mm
3 and mice were
randomly divided into four groups (n = 5 per group).
The control group was left untreated. The 3 treatment
groups consisted of the Ad-vectors, Ad-CALR and the
Ad-CALR/MAGEA-3. Each of the mice in the 3 treat-
ment groups were injected intratumorally with 100 μL
of the respective treatment once every 7 days, for a total
of 5 injections. The tumor diameters were measured 2
times per week with a caliper. The tumor volume
(mm
3) was calculated as: (length × width
2)/2. All mice
were euthanized humanely after 5 treatments, and the
resected tumors were weighed.
Statistical analyses
Statistical analyses were performed using Statistical
Package for the Social Sciences version 16.0 software
(SPSS, Chicago, IL). Data were expressed as mean ±
standard deviation (SD), and analyzed using the Q-test
or analysis of variance (ANOVA). The level of signifi-
cance was set at P < 0.05.
Results
Identification of MOI in glioblastoma cell line U87
To verify the transfection efficiency of Ad-vector in U87
cells, uptake of fluorescently-labeled Ad-vector (MOI
50, 100, 200) was detected by fluorescence microscopy
24 and 48 h after transfection. The test showed high-
efficiency transfection: > 90% of cells displayed green
fluorescence 48 h after transfection with 100 MOI Ad-
enhanced GFP (EGFP; Figure 1).
Expression of CALR and MAGE-A3 is examined by PCR
and Western blot
To testify to the expression of CALR and MAGE-A3
and examine the differences among the four treatment
groups, RT-PCR, qRT-PCR and Western blot were per-
formed. The results of qRT-PCR showed that there
were differences in CALR gene expression in U87 cells
among the treatment groups. U87 transfected with Ad-
CALR or Ad-CALR/MAGE-A3 expressed higher levels
of CALR (Figure 2A). The results of RT-PCR showed
that MAGE-A3 was expressed in each treatment group
of U87 cells (Figure 2B). However, the transfection of
MAGE-3A in U87 cells, demonstrated by the expression
of MAGE-A3/PolyA, was demonstrated only in the Ad-
CALR/MAGE-A3-transfected group (Figure 2B). Results
of the Western blot indicated that CALR and MAGE-
A3 protein was expressed in U87 cells of all treatment
groups (Figure 2C).
Inhibition of cell proliferation
The effect of Ad-CALR/MAGE-A3 transfection on glio-
blastoma cell proliferation was determined by MTT
assay. The inhibition of cell proliferation was calculated
as one minus the optical density reading taken at 490
nm. During the post-transfection observation period of
24-96 h, the proliferation of U87 cells transfected with
Ad-CALR/MAGE-A3 was significantly inhibited in a
time-dependent manner beginning at 48 h, when com-
pared with the null, Ad-vector and Ad-CALR groups
(Figure 3).
Attenuation of invasion ability in Ad-CALR/MAGE-A3-
transfected cells
Tumor cell invasion is the critical step in the metastatic
process. To verify the effect of Ad-CALR/MAGE-A3 on
invasion ability, U87 cells were assayed using Transwell
chambers pre-coated with Matrigel. After 48 h incuba-
tion, the invasive potential of Ad-CALR/MAGE-A3-
transfected U87 cells was significantly suppressed, com-
pared with the other groups (Figure 4). These results
suggested that Ad-CALR/MAGE-A3 transfection attenu-
ated the metastatic potential of glioblastoma cells in
vitro.
Flow cytometry indicate non-apoptotic effect on U87 of
Ad vectors
To evaluate further whether Ad-mediated transfer of the
genes of interest induced apoptosis in transfected U87
cells, 48 h after transfection cells were harvested and
Figure 1 Identificcation of MOI in glioblastoma cells. Detection of MOI by fluorescence microscopy. A: under ordinary light; B: under
fluorescence light; C: superimposed image of the two images. Optimal MOI of transfection with Ad-EGFP (green) in U87 cells were easily
identified for 48 h post-transfection (×100).
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the null, Ad-vector, Ad-CALR and Ad-CALR/MAGE-A3
groups were 10.50%, 15.28%, 12.68% and 21.39%, respec-
tively, and demonstrated that Ad-CALR/MAGE-A3
inducing apoptosis effect (Figure 5).
Inhibition of tube formation in human umbilical vein
endothelial cells
Angiogenesis is the critical step in tumor initiation and
progression. To determine the effect of Ad-CALR/MAGE-
A3 on angiogenesis, tube formation in HUVEC cells was
assayed. After treatment with the different supernatants
for 48 h, the number of tubes formed was less in the Ad-
CALR and Ad-CALR/MAGE-A3 groups than the other
two groups (Figure 6). The ability of HUVEC cells to form
tubes was significantly compromised by Ad-CALR/
MAGE-A3. These data demonstrate that the antiangio-
genic effect of transfection with combined CALR and
MAGE-A3 was similar to that of transfection with CALR
only.
Molecular mechanisms underlying the antitumor effects
of Ad-CALR/MAGE-A3
The protein from transfected cells was extracted to
examine the effects of Ad-CALR/MAGE-A3 on some
important cytokines and signaling molecules. After 48 h
of transfection, the relative expression levels of the pro-
teins PI3K, p-Akt, and p-Erk1/2 in the Ad-CALR/
MAGE-A3 group were decreased, while there were no
differences in the Ad-vector and Ad-CALR groups. The
reduction was more significant after 96 h of transfection
(Figure 7). Furthermore, compared to other groups,
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Figure 2 Transfection of Ad-CALR/MAGE-A3 into glioblastoma cells. (A): Comparision of expression of CALR in each group of U87 cells by
quantitative RT-PCR. (B): Identification of expression of MAGE-A3 and MAGE-A3/PolyA by RT-PCR. (C): Identification of expression of CALR and
MAGE-A3 in each grou of U87 cells by Western blotting.
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Figure 3 Transfection of Ad-CALR/MAGE-A3 inhibited cell proliferation of glioblastoma cells in vitro. Ad-CALR/MAGE-A3 transfected U87
cell growth was significantly attenuated in a time-dependent manner compared with control, Ad and Ad-CALR group. *P < 0.01.
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MMP2 and MMP9 expression (Figure 7). These data
demonstrated that transfection with Ad-CALR/MAGE-
A3 may inhibit signal transducer and activator of tran-
scription (STAT)3, MMP2, and MMP9, which all play
an important role in tumor progression.
Inhibition of tumor growth of glioblastoma cells in nude
mice by Ad-CALR/MAGE-A3
Intra-tumoral injection with adenoviral vectors was per-
formed to investigate whether Ad-CALR/MAGE-A3 had
the effect of inhibition on tumor growth in vivo. A
nude-mouse xenograft model of human glioblastoma
was established, and when the tumor volume reached
50-100 mm
3, intra-tumoral treatment with Ad-vectors
were started and repeated every 7 days for a total of 5
injections. The mean tumor volume of the Ad-CALR/
MAGE-A3 group from day 25 to the end was signifi-
cantly smaller than that of the other groups, whereas
there was no statistical differences among the other
groups throughout the experimental period (Figure 8A).
All mice were euthanized on the 42
nd day, and the final
tumor volume and weight in the Ad-CALR/MAGE-A3
group (142.6 ± 84.2 mm
3 and 0.18 ± 0.10 g, respec-
tively) were markedly smaller than in the null (724.2 ±
198.4 mm
3 and 0.71 ± 0.18 g), Ad-vector (701.4 ± 183.2
Figure 4 Transfection of Ad-CALR/MAGE-A3 attenuated the invasion ability of glioblastoma cells in vitro. Using matrigel coated invasion
chambers, cell invasion ability was observed. The invading cells were fixed with cold methanol, and then stained with crystal violet.
Representative microscopy images of the invasion assay are shown (×100). (A) - (D):Photomicrographs showing representative views of cell
invasion assays. In the presence of Ad-CALR/MAGE-A3, the number of invading U87 (D) was smaller than those of U87 (A), U87/Ad-vector (B)
cells and U87/Ad-CALR(C). Scale bars = 100 μm. (E): Bar represents the mean number of the cells per field. The invasion assay was consistent
with the migration assay and showed that the transfection of Ad-CALR/MAGE-A3 attenuated the invasion ability of glioblastoma cells. *p < o.o5.
Figure 5 Transfection of Ad-CALR/MAGE-A3 induced apoptosis of glioblastoma cells. The transfected cells, labeled with AnnexinV-FITC and
PI, were subjected to floe cytometric analysis. Two parameter histogram Dot Plot displayed FL1-FITC on the x axis and FL2-PI on the y axis. The
result showed that Ad-CALR/MAGE-A3 increased the apoptotic rate in U87 cells.
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3 and 0.65 ± 0.14 g) and Ad-CALR (659.2 ± 147.8
mm
3 and 0.58 ± 0.12 g) groups (n = 5, each group; Fig-
ure 8B). In addition, the relative protein expression of
CALR in the Ad-CALR/MAGE-A3 group was increased
significantly (Figure 9). Altogether, these results indicate
that intratumoral injection with Ad-CALR/MAGE-A3
suppressed the tumor growth of glioblastoma cells in
vivo.
Discussion
Glioblastoma is the most common and aggressive form of
brain tumor that affects adults. Despite advances in surgi-
cal and clinical neuro-oncology, the prognosis for glio-
blastoma remains poor due to its diffuse and invasive
nature [24]; tumor cells are highly proliferative and inva-
sive within the brain. Tumor progression involves tumor
cell proliferation and invasion, vascular intravasation and
extravasation, establishment of a metastatic niche, and
angiogenesis [25-27]. Therefore, to improve outcome the
focus of gene therapy strategy is to effectively inhibit the
proliferative, invasive, and angiogenic behavior of glio-
blastoma cells.
Studies have shown that CALR plays an important role
in the biological processes of many cancers, and these
mechanisms are mediated via antiangiogenic factors and
the immune response. There is wide recognition that in
glioblastoma, CALR expression is increased, with high
radiation sensitivity [28]. However, a definite conclusion
that the expression of CALR with MAGE-A3 in glioblas-
toma affects tumor cell proliferation, apoptosis, and inva-
sion processes has not been established.
In order to evaluate the effect of Ad-CALR/MAGE-A3
on U87 glioblastoma cells, we over-expressed human
CALR and MAGE-A3 in U87 cells via adenovirus-
Figure 6 Effect of Ad-CALR/MAGE-A3 on anti-angiogenesis in vitro. Using matrigel coated 96 well plates, anti-angiogenesis ability was
observed. (A) - (D): Photomicrographs showing representative views of tube formation assays. In the presence of Ad-CALR(C) or Ad-CALR/MAGE-
A3(D), the number of connecting HUVEC was smaller than those of Null (A) and Ad-vector (B). Scale bars = 100 μm. (E): Bar represents the mean
number of the cells per field. The tube formation assay showed that the transfection of Ad-CALR/MAGE-A3 attenuated the tube formation ability
of HUVEC cells. Data are presented as mean ± SD (*P < 0.05, compared with HUVEC or HUVEC/Ad-VECTOR, P > 0.05, compared with HUVEC/Ad-
CALR group).
Figure 7 Western blot analysis of PI3K/AKT、Erk1/2 and MMP-
2/-9 by transfecting with Ad-CALR/MAGE-A3 in glioblastoma
cells in vitro. Representative images were shown. Expression of
PI3K/AKT、Erk1/2 and MMP-2/-9 in Ad-CALR/MAGE-A3 group was
significantly suppressed compared to that in other groups.
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appropriate number of PFUs (MOI = 100) to obtain high
expression of CALR and MAGE-A3. The present in vitro
study demonstrated that the proliferative and invasive
properties of cells transfected with Ad-CALR/MAGE-A3
were attenuated in comparison to the other treatment
groups and controls. The in vivo study demonstrated
that the tumor formation rate, and the average tumor
growth rate, of the Ad-CALR/MAGE-A3-transfected
group was significantly lower than that of the non-trans-
fected, Ad-vector-transfected and Ad-CALR-transfected
groups. Thus, these results s u g g e s tt h a ta nA d - v e c t o r
encoding CALR chimerically linked to MAGE-A3 is a
unique approach for the generation of a potent antitumor
effect.
In the current study, CALR and MAGE-A3 overex-
pression in glioblastoma cells suppressed the Erk1/2
MAPK and PI3K/Akt signal pathways, which are well
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groups. (B): Bar represented that the tumor weight of Ad-CALR/MAGE-A3 group was decreased than that of control, Ad and Ad-CALR groups.
**P < 0.01 versus other groups.
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Page 8 of 10recognized for mediating cell proliferation and apopto-
sis. This result explains, at least in part, why Ad-CALR/
MAGE-A3 inhibited cell proliferation and induced
apoptosis in U87 cells.
Furthermore, the expressions of MMP2 and MMP9
were downregulated in Ad-CALR/MAGE-A3- trans-
fected cells, and this may suggest that these MMPs are
the downstream products of CALR and MAGE-A3-
induced cell signaling. MMPs are a family of enzymes
that degrade proteins in the extracellular matrices of tis-
sues, and are clearly involved in stages of cancer progres-
sion, including tumor cell degradation of basement
membranes and stroma, and blood vessel penetration
[29,30]. Consequently, the reduction of MMP2 and
MMP9 by Ad-CALR/MAGE-A3 will attenuate the meta-
static potency of glioblastoma cells. Ad-CALR/MAGE-
A3 also generated a therapeutic effect due to inhibition
of angiogenesis.
Tumor growth and metastasis formation depends on
an adequate blood supply. As neoplasms grow larger,
blood supply to the tumor is often ensured by new vessel
formation, a process termed angiogenesis. Therapeutic
agents that target tumor vasculature may prevent or
delay tumor growth and even promote tumor regression
or dormancy [31,32]. Previous studies demonstrated the
CALR and its protein fragment (aa 1-180) vasostatin are
endothelial cell inhibitors of tumor growth [33,34].
Therefore, gene therapy employing CALR may enhance
antitumor responses and antiangiogenic effects. In the
present study, the tube formation assay showed that Ad-
CALR/MAGE-A3 attenuated the angiogenic potential of
glioblastoma cells.
In this study, we constructed an innovative adenoviral
vector Ad-CALR/MAGE-A3. Our results demonstrate
that Ad-CALR/MAGE-A3 can significantly suppress the
invasive potency of U87 cells. Furthermore, transfection
with Ad-CALR/MAGE-A3 resulted in the inhibition of
angiogenesis. Thus, adenoviral-mediated delivery of
CALR chimerically linked to MAGE-A3 represents a
unique approach for the generation of potent antitumor
effects.
Conclusions
In summary, our findings show for the first time that
overexpression of CALR and MAGE-A3 in glioblastoma
cells by Ad-CALR/MAGE-A3 transfection can inhibit
tumor growth and invasion in vitro and in vivo. Further-
more, these antitumor effects may be associated with
antiangiogenesis in glioblastoma. Therefore, Ad-CALR/
MAGE-A3 may potentially be a useful tool for gene
therapy of glioblastoma, and even other cancers.
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